Q-omics provides the consensus-scored SCCPDH profile across patient tissues and cancer cell-line models. SCCPDH expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SCCPDH is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, SCCPDH protein abundance shows 22,772 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, THCA, and GBM as cancer lineages where SCCPDH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCCPDH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCCPDH survival associations across molecular data types. SCCPDH RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCCPDH RNA expression–survival associations across cancer types. High SCCPDH expression shows unfavorable associations in UVM, KIRP, ACC and HNSC, but favorable associations in KIRC and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SCCPDH RNA expression.
This table summarizes SCCPDH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SCCPDH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCCPDH shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in BRCA, LIHC and HNSC. The THCA box plot shows higher SCCPDH RNA expression in normal versus tumor tissue (log2 FC = −0.398, t-test p < 0.001).
This table shows molecular features associated with SCCPDH in patient tissues and cancer cell lines. In patient samples, SCCPDH shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SCCPDH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
